Search

Besilesomab

Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the … Besilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis

Anisotropine methylbromide

action on the bile ducts and gallbladder. … Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents.

Tolrestat

While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. … Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications.

Phloxine B

Phloxine B (commonly known simply as phloxine, also known as D&C RED NO. 28) is a color additive which is used both as an inactive ingredient to provide color to products, or as a colorant in dental disclosing

Pegunigalsidase alfa

[A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease. … While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, pegunigalsidase alfa carries no M6P on its glycans and does not depend on the M6P receptor during cellular

Bremelanotide

[A179683] Since then it was investigated for its place in treating sexual dysfunction in men and women but is now only indicated for women. … [L9635] Bremelanotide was first described in the literature in 2003 when it was known by the investigational code PT-141.

Hydroxyethyl ethylcellulose

Hydroxyethyl ethylcellulose modulates bacterial binding to salivary pellicle; moderately effective in preventing plaque formation.

Ferrous cysteine glycinate

Tiratricol

[A274073] Tiratricol is currently being investigated in US clinical trials. … Tiratricol is an analogue and active metabolite of the thyroid hormone triiodothyronine (T3).

Lumasiran

[L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. … [L23554] Lumasiran was granted FDA approval on 23 November 2020.[L23394]